BeyondSpring presents plans for 442-patient Phase 3 plinabulin trial in lung cancer
BYSI•BeyondSpring plans to start its 442-patient DUBLIN-4 Phase 3 trial in 2026-2027, comparing plinabulin plus docetaxel with docetaxel for certain patients with non-small cell lung cancer. An interim analysis is expected in 2028.
1. Trial plans
BeyondSpring plans to start the confirmatory DUBLIN-4 Phase 3 trial in 2026-2027. The study will compare plinabulin plus docetaxel with docetaxel in patients with post-immunotherapy, driver-negative, non-squamous non-small cell lung cancer; overall survival is the primary endpoint.
2. Enrollment and analysis
The trial is planned to enroll 442 patients evenly between China and Western regions. An interim analysis is expected in 2028 after 221 progression-free survival events. DUBLIN-4 has FDA Fast Track designation.
